Hoey Investments’s Iovance Biotherapeutics IOVA Stock Holding History

Hoey Investments’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.16K	Hold	1,000	–	–	﹤0.01%	308
2026 Q1	$3.51K	Hold	1,000	–	–	﹤0.01%	305
2025 Q4	$2.73K	Sell	1,000 -1,000	-50%	-$2.31K	﹤0.01%	334
2025 Q3	$4.34K	Hold	2,000	–	–	﹤0.01%	293
2025 Q2	$3.44K	Hold	2,000	–	–	﹤0.01%	309
2025 Q1	$6.66K	Buy	+2,000	New	+$10.3K	﹤0.01%	231

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Hoey Investments's IOVA Position: Q2 2026 in Review

Hoey Investments held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 1,000 shares worth $4.16K. The position accounts for ﹤0.01% of the portfolio, ranked #308.

Hoey Investments first reported a position in IOVA in Q1 2025 and has held it in 6 quarters since. The position peaked at $6.66K in Q1 2025. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Hoey Investments held 1,000 shares of Iovance Biotherapeutics worth $4.16K as of Q2 2026.
Hoey Investments left its Iovance Biotherapeutics share count unchanged in Q2 2026.
Iovance Biotherapeutics made up ﹤0.01% of Hoey Investments's portfolio in Q2 2026, its #308 holding.
Hoey Investments first reported a position in Iovance Biotherapeutics in Q1 2025 and has held it in 6 quarters since.
Hoey Investments's Iovance Biotherapeutics position peaked at $6.66K in Q1 2025.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Hoey Investments's 13F filing for Q2 2026, filed 27 Jul 2026.